\
&
Contact us
\
&
Contact us
NCP Flanders is conducting a short satisfaction survey to gather valuable feedback and suggestions on the NCP services. The survey is organised into three sections: NCP Flanders assistance, info sessions, and NCP Flanders website & LinkedIn. If you are not familiar with one of these sections, the survey will automatically guide you to the next section. The survey is fully anonymous and will remain open until 24 July 2026. The NCP Flanders team would greatly appreciate it if you could take a few minutes to fill in the survey and provide your opinion via this link. If you would like to get in touch NCP Flanders, please mail to info@ncpflanders.be
EIT Health has published the 2026 Transformative Healthcare Instrument call. It is designed to support high-potential European healthcare start-ups as they move product development forward, improve commercialisation plans and prepare for further fundraising. The programme focuses on unmet clinical needs across Europe.Eligible applicants are private SMEs with at least 4 full-time equivalent employees and a minimum total equity investment of €2,000,000 closed within the previous 36 months, including at least one new investor. Projects must meet minimum Innovation Maturity Levels: IML 5 or above for biotech, IML 6 or above for medtech, and IML 7 or above for digital health and for biomarkers or diagnostics.Projects may request €300,000 to €500,000 from EIT Health, covering up to 50% of total project costs, with the remaining 50% to come from other sources.You can find further information about the call on this website. The call will close on 16 September 2026. An open Q&A session about the call is organised by EIT Health on 2 September at 11 am. Interested? Register here Background: The European institute of Innovation and Technology (EIT) stands at the crossroad of business creation, innovation and education. It consists of ten knowledge and innovation communities, including the EIT health community. The overall objective is to transform promising innovations into succesful companies.
The Request for Proposal covers the Next Generation Rotorcraft Capability Concept Design phase and asks each of the four pre-qualified bidders to propose up to two concept design solutions. The package also includes an offer for de-risking activities to help mature the proposed designs in an initial step of incremental development. According to NSPA, the RFP is based on a harmonised operational and technical baseline developed with Canada, France, Germany, Italy, the Netherlands and the United Kingdom. This baseline includes key performance parameters linked to capability and supportability requirements, together with operational mission scenarios. NSPA says the procurement is the first it has launched under its new “Acquisition by Qualified Options” competitive mechanism. Bid evaluation is planned to finish by the end of 2027, after which NSPA aims to submit an evaluation summary report to the participating nations. The agency also plans to use digital trials in an in-house modelling and simulation environment as part of the operational evaluation. More information is available at https://eportal.nspa.nato.int/eProcurement5G/Opportunities/Opportunities/DetailsOpportunity?RowIDEncrypted=wKb0O1orsbsor1liAAE4Ig&index=3 and https://www.nspa.nato.int/news/2026/nspa-releases-rfp-for-next-generation-rotorcraft-capability-concept-design
The call identifier is EDF-EDIP-USI-2026-LS-IRA. It sits under EDIP’s Ukraine Support Instrument and is designed for Industry Reinforcement Actions linked to missiles, ammunition and bombs. Eligible consortia must include at least one legal entity in Ukraine. The deadline for submitting proposals is 13 October 2026. Further details are available on the EU Funding & Tenders Portal: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/calls-for-proposals?order=DESC&pageNumber=1&pageSize=50&sortBy=startDate&isExactMatch=true&status=31094501,31094502,31094503&callIdentifier=EDF-EDIP-USI-2026-LS-IRA See also our previous news item: https://ncpflanders.be/news/edip-opens-first-industry-reinforcement-call
Development actions implemented via lump sum grants targeting disruptive technologies for defence EDF-2026-LS-DA-DIS-OTHR European Defence Fund (EDF) 10 August 2026 On 13 July 2026, the European Union and Ukraine signed the Association Agreement on the participation of Ukraine in the European Defence Fund (EDF). This Association Agreement will formally enter into force once the Parties have notified each other of the completion of their respective internal procedures necessary for that purpose. When the Association Agreement will enter into force, legal entities established in Ukraine will become eligible as beneficiaries and subcontractors involved in the actions supported by the EDF under the conditions laid down in Regulation (EU) 2021/697. In the meantime, Ukrainian legal entities may already apply and be considered as consortium members for the EDF Calls for proposals for 2026. For more information see QnA.
Sign up for personalised information!
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you. By signing up, you can opt in for email notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
